IDEXX Laboratories, Inc. logo
IDEXX Laboratories, Inc. (IDXX)
Compare

IDEXX Laboratories, Inc. (IDXX) Debt to Assets Ratio: 0.32%

The debt to assets ratio for IDEXX Laboratories, Inc. (IDXX) is 0.32% as of Tuesday, June 9, 2026.

IDXX Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

0.32%

IDXX Competitors' Debt to Assets Ratio

NAMEMARKET CAPDEBT TO ASSETS RATIO
IDEXX Laboratories, Inc. (IDXX)0.32%
Humana Inc. (HUM)$43.60B0.27%
Agilent Technologies, Inc. (A)$38.26B0.26%
Zoetis Inc. (ZTS)$34.46B0.61%
Centene Corporation (CNC)$32.69B0.24%
IQVIA Holdings Inc. (IQV)$31.09B0.54%
DexCom, Inc. (DXCM)$30.17B0.22%
Biogen Inc. (BIIB)$29.39B0.24%
Regeneron Pharmaceuticals, Inc. (REGN)$63.48B0.07%
Veeva Systems Inc. (VEEV)$27.37B0.01%

Leverage Ratios Comparison

Debt/Assets

0.3%

Debt/Equity

0.67

Current Ratio

1.17

Interest Coverage

35.5x

Formula: Debt/Assets = Total Debt / Total Assets × 100

Debt/Assets vs Debt/Equity:

  • Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
  • Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
  • Both measure leverage but from different perspectives

Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.

IDEXX Laboratories, Inc. Debt to Assets Ratio Formula & Definition

Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IDEXX Laboratories, Inc. Debt to Assets Ratio FAQ

What is the debt to assets ratio for IDEXX Laboratories, Inc. (IDXX)?
The debt to assets ratio for IDXX stock is 0.32%.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Westbrook, ME
11,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Jonathan J. Mazelsky